COMPACT Phase III Clinical Trial Results

Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:

Folder: MultiVuVideo

Uploaded: Mar 23, 2017

Views: 5

Likes: 0

Tags: CSL Behring, Global, biotherapeutics, Medicine, study, research, FDA, healthcare, health, MultiVu 8056151

published 1 year ago